26 results
8-K
EX-99.2
CGTX
Cognition Therapeutics Inc
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
period and 3 in placebo period) Most common AEs by MedDRA system organ class: - GI: nausea, diarrhea - Injury & procedural complications: procedural
424B4
CGTX
Cognition Therapeutics Inc
14 Nov 22
Prospectus supplement with pricing info
6:02am
effects of our product candidates could result in patient injury or death. Any of these occurrences may materially and adversely affect our business … greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise
DRS
rhm2p5d
20 Oct 22
Draft registration statement
12:00am
10-K
ofr442e4ja5wzfg1
30 Mar 22
Annual report
7:40am
8-K
EX-99.1
rvjd4s0guto8hughp9
10 Jan 22
Regulation FD Disclosure
7:01am
10-Q
lffjhce
17 Nov 21
Quarterly report
5:15pm
424B4
e3cc8zyax6gud
12 Oct 21
Prospectus supplement with pricing info
4:11pm
S-1
EX-10.15
f2qho2wd fy
19 Jul 21
IPO registration
7:02am
S-1
EX-10.17
ozwiog j2ouvy
19 Jul 21
IPO registration
7:02am
S-1
60ao2376bbcji34xd7
19 Jul 21
IPO registration
7:02am
S-1
EX-10.4
xj87hbrtzfvz7um
19 Jul 21
IPO registration
7:02am
S-1
EX-10.6
3n8 9q6fs
19 Jul 21
IPO registration
7:02am
S-1
EX-10.18
2dx lqpc04v0evm97f
19 Jul 21
IPO registration
7:02am